- Home
- NRIX vs VIR Comparison
NRIX vs VIR Comparison
Compare NRIX & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRIX | VIR |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NRIX | VIR |
|---|---|---|
| Price | $17.50 | $10.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $30.50 | $19.63 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 04-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $76,987,000.00 | $68,556,000.00 |
| Revenue This Year | N/A | $270.22 |
| Revenue Next Year | $40.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 99.31 | N/A |
| 52 Week Low | $8.20 | $4.16 |
| 52 Week High | $22.50 | $10.91 |
Technical Indicators
Market Signals| Indicator | NRIX | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 64.82 | 66.51 |
| Support Level | $16.81 | $5.18 |
| Resistance Level | $19.98 | $10.91 |
| Average True Range (ATR) | 0.92 | 0.47 |
| MACD | 0.23 | 0.13 |
| Stochastic Oscillator | 96.64 | 95.34 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.